243 related articles for article (PubMed ID: 30705097)
41. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
42. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
[TBL] [Abstract][Full Text] [Related]
43. Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia.
van der Sluis I; Möricke A; Escherich G; von Stackelberg A; Holter W; Klingebiel T; Flotho C; Legien S; Tissing W; Bierings M; Guimbal-Schmolck C; Pichlmeier U; Kühnel HJ; Pieters R
Haematologica; 2013 Nov; 98(11):1697-701. PubMed ID: 23753025
[TBL] [Abstract][Full Text] [Related]
44. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
[TBL] [Abstract][Full Text] [Related]
45. [Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia].
Pawińska K; Balwierz W; Sztefko K; Czogała M
Przegl Lek; 2006; 63(1):44-6. PubMed ID: 16892900
[TBL] [Abstract][Full Text] [Related]
46. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
[TBL] [Abstract][Full Text] [Related]
47. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.
Hunault-Berger M; Leguay T; Huguet F; Leprêtre S; Deconinck E; Ojeda-Uribe M; Bonmati C; Escoffre-Barbe M; Bories P; Himberlin C; Chevallier P; Rousselot P; Reman O; Boulland ML; Lissandre S; Turlure P; Bouscary D; Sanhes L; Legrand O; Lafage-Pochitaloff M; Béné MC; Liens D; Godfrin Y; Ifrah N; Dombret H;
Am J Hematol; 2015 Sep; 90(9):811-8. PubMed ID: 26094614
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
49. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
50. Asparaginase activity monitoring in pediatric acute lymphoblastic leukemia: A cross-sectional nationwide study in Spain.
Lassaletta Á; Gutiérrez F;
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1729. PubMed ID: 36307379
[TBL] [Abstract][Full Text] [Related]
51. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
52. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Piatkowska-Jakubas B; Krawczyk-Kuliś M; Giebel S; Adamczyk-Cioch M; Czyz A; Lech Marańda E; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
Pol Arch Med Wewn; 2008 Nov; 118(11):664-9. PubMed ID: 19140571
[TBL] [Abstract][Full Text] [Related]
53. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.
Taylor CW; Dorr RT; Fanta P; Hersh EM; Salmon SE
Cancer Chemother Pharmacol; 2001; 47(1):83-8. PubMed ID: 11221967
[TBL] [Abstract][Full Text] [Related]
54. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.
Müller HJ; Beier R; da Palma JC; Lanvers C; Ahlke E; von Schütz V; Gunkel M; Horn A; Schrappe M; Henze G; Kranz K; Boos J
Cancer Chemother Pharmacol; 2002 Feb; 49(2):149-54. PubMed ID: 11862429
[TBL] [Abstract][Full Text] [Related]
55. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
[TBL] [Abstract][Full Text] [Related]
56. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
57. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
58. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
59. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
60. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
